9H-fluoren-9-one O-methyl oxime | 100725-41-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 9H-fluoren-9-one O-methyl oxime
• 英文别名: N-methoxy-9-fluorenylideneamine；9-fluorenone methoxyimine；fluoren-9-one-(O-methyl oxime )；Fluoren-9-on-(O-methyl-oxim)；Fluorenonoximmethylaether；Fluorenon-(9)-O-methyloxim；N-methoxyfluoren-9-imine
• CAS: 100725-41-5
• 化学式: C₁₄H₁₁NO
• 分子量: 209.247
• InChiKey: MNCQRDMUOBPJCR-UHFFFAOYSA-N

物化性质

• 熔点：
  48-50 °C
• 沸点：
  370.9±25.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  9H-fluoren-9-one O-methyl oxime 在 aluminum (III) chloride 、 溴 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 1.0h， 生成 3-bromo-9-fluorenone methoxyimine
  参考文献：
  名称：

  一种3-溴芴酮的制备方法

  摘要：

  本发明属于芴类化合物制备技术领域，尤其涉及一种3‑溴芴酮的制备方法，包括以下步骤：A、肟化反应：将芴酮与盐酸甲氧胺加入到溶剂中，进行肟化反应，反应淬灭处理后得到芴酮甲氧基肟；B、溴代反应：将催化剂、溴素以及步骤A中得到的芴酮甲氧基肟加入到溶剂中，反应淬灭处理后，得到溴代产物；C、水解反应：将步骤B中得到的溴代产物加入到溶剂中，并在50‑100℃条件下水解反应得到3‑溴芴酮，其制备方法简单，成本低，得到的3‑溴芴酮收率高、纯度高，反应条件温和，适于工业化生产。

  公开号：

  CN107056595B
• 作为产物：
  描述：

  biphenyl-2-carbaldehyde O-methyl oxime 在 palladium diacetate 、 三氟乙酸 、 silver(l) oxide 作用下， 反应 18.0h， 以87%的产率得到9H-fluoren-9-one O-methyl oxime
  参考文献：
  名称：

  钯催化双CH活化和Heck环化反应由芳族醛肟肟醚和芳基卤化物合成芴酮。

  摘要：

  DOI：

  10.1002/anie.200804153

文献信息

• Pd-Catalyzed Multiple CH Functionalization to Construct Biologically Active Compounds from Aryl Aldoxime Ethers with Arenes
  作者：Vedhagiri S. Thirunavukkarasu、Chien-Hong Cheng

  DOI：10.1002/chem.201102996

  日期：2011.12.23

  Functional fluorenones: Aromatic aldoxime ethers react with unactivated arenes catalyzed by palladium complexes to give biologically active fluoren‐9‐ones (see scheme). Multiple CH bond activation and an oxidative cyclization are involved in the reaction.

  功能性芴酮：芳族醛肟肟醚与钯配合物催化的未活化芳烃反应，生成具有生物活性的荧光9-9（见方案）。该反应涉及多个CH键活化和氧化环化作用。
• Schmidt,J.; Soell, Chemische Berichte, 1907, vol. 40, p. 4258
  作者：Schmidt,J.、Soell

  DOI：——

  日期：——
• MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20070281885A1

  公开（公告）日：2007-12-06

  The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20080125444A1

  公开（公告）日：2008-05-29

  The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• OXIMYL HCV SERINE PROTEASE INHIBITORS
  申请人：GAI YONGHUA

  公开号：US20090155210A1

  公开（公告）日：2009-06-18

  The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.